Evanson Asset Management LLC Has $568,000 Stock Position in Eli Lilly and Company (NYSE:LLY)

Evanson Asset Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 24.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,211 shares of the company’s stock after purchasing an additional 240 shares during the quarter. Evanson Asset Management LLC’s holdings in Eli Lilly and Company were worth $568,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Silicon Valley Capital Partners acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $25,000. Bogart Wealth LLC boosted its position in shares of Eli Lilly and Company by 193.3% in the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after buying an additional 58 shares during the period. Laffer Tengler Investments acquired a new stake in shares of Eli Lilly and Company in the first quarter worth $33,000. Raleigh Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 156.4% in the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after buying an additional 61 shares during the period. Finally, Tanglewood Legacy Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $37,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the sale, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the sale, the executive vice president now owns 7,760 shares in the company, valued at $4,586,004.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the sale, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,010,309 shares of company stock valued at $21,095,701,670. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $575.66 on Friday. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.84. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The stock has a market capitalization of $546.47 billion, a PE ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32. The stock has a 50-day simple moving average of $512.56 and a 200 day simple moving average of $438.41.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. During the same quarter last year, the company posted $1.25 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 9.84 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a dividend yield of 0.79%. Eli Lilly and Company’s payout ratio is 62.87%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on LLY shares. Berenberg Bank upped their target price on Eli Lilly and Company from $375.00 to $500.00 in a report on Tuesday, June 20th. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the company a “neutral” rating in a research note on Wednesday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a research note on Wednesday, August 9th. Finally, Citigroup upped their target price on Eli Lilly and Company from $360.00 to $525.00 and gave the stock a “buy” rating in a research report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $532.78.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.